TY - JOUR AU - Chen, W. AU - Zheng, R. AU - Baade, P. D. AU - Zhang, S. AU - Zeng, H. AU - Bray, F. PY - 2016 DA - 2016// TI - Cancer statistics in China, 2015 JO - CA Cancer J Clin VL - 66 UR - https://doi.org/10.3322/caac.21338 DO - 10.3322/caac.21338 ID - Chen2016 ER - TY - JOUR AU - Chen, W. AU - Xia, C. AU - Zheng, R. AU - Zhou, M. AU - Lin, C. AU - Zeng, H. PY - 2019 DA - 2019// TI - Disparities by province, age, and sex in site-specific cancer burden attributable to 23 potentially modifiable risk factors in China: a comparative risk assessment JO - Lancet Glob Health VL - 7 UR - https://doi.org/10.1016/S2214-109X(18)30488-1 DO - 10.1016/S2214-109X(18)30488-1 ID - Chen2019 ER - TY - JOUR AU - Blanchard, P. AU - Lee, A. AU - Marguet, S. AU - Leclercq, J. AU - Ng, W. T. AU - Ma, J. PY - 2015 DA - 2015// TI - Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis JO - Lancet Oncol. VL - 16 UR - https://doi.org/10.1016/S1470-2045(15)70126-9 DO - 10.1016/S1470-2045(15)70126-9 ID - Blanchard2015 ER - TY - JOUR AU - Yang, L. AU - Xia, L. AU - Wang, Y. AU - He, S. AU - Chen, H. AU - Liang, S. PY - 2017 DA - 2017// TI - Development and external validation of nomograms to predict the risk of skeletal metastasis at the time of diagnosis and skeletal metastasis-free survival in nasopharyngeal carcinoma JO - BMC Cancer VL - 17 UR - https://doi.org/10.1186/s12885-017-3630-9 DO - 10.1186/s12885-017-3630-9 ID - Yang2017 ER - TY - JOUR AU - Lee, A. W. AU - Ma, B. B. AU - Ng, W. T. AU - Chan, A. T. PY - 2015 DA - 2015// TI - Management of Nasopharyngeal Carcinoma: current practice and future perspective JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2015.60.9347 DO - 10.1200/JCO.2015.60.9347 ID - Lee2015 ER - TY - JOUR AU - Zhang, L. AU - Huang, Y. AU - Hong, S. AU - Yang, Y. AU - Yu, G. AU - Jia, J. PY - 2016 DA - 2016// TI - Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial JO - Lancet. VL - 388 UR - https://doi.org/10.1016/S0140-6736(16)31388-5 DO - 10.1016/S0140-6736(16)31388-5 ID - Zhang2016 ER - TY - JOUR AU - Xiao, G. AU - Cao, Y. AU - Qiu, X. AU - Wang, W. AU - Wang, Y. PY - 2013 DA - 2013// TI - Influence of gender and age on the survival of patients with nasopharyngeal carcinoma JO - BMC Cancer VL - 13 UR - https://doi.org/10.1186/1471-2407-13-226 DO - 10.1186/1471-2407-13-226 ID - Xiao2013 ER - TY - JOUR AU - Tang, X. R. AU - Li, Y. Q. AU - Liang, S. B. AU - Jiang, W. AU - Liu, F. AU - Ge, W. X. PY - 2018 DA - 2018// TI - Development and validation of a gene expression-based signature to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma: a retrospective, multicentre, cohort study JO - Lancet Oncol VL - 19 UR - https://doi.org/10.1016/S1470-2045(18)30080-9 DO - 10.1016/S1470-2045(18)30080-9 ID - Tang2018 ER - TY - JOUR AU - Ono, T. AU - Azuma, K. AU - Kawahara, A. AU - Sasada, T. AU - Matsuo, N. AU - Kakuma, T. PY - 2018 DA - 2018// TI - Prognostic stratification of patients with nasopharyngeal carcinoma based on tumor immune microenvironment JO - Head Neck VL - 40 UR - https://doi.org/10.1002/hed.25189 DO - 10.1002/hed.25189 ID - Ono2018 ER - TY - JOUR AU - Cho, Y. A. AU - Yoon, H. J. AU - Lee, J. I. AU - Hong, S. P. AU - Hong, S. D. PY - 2011 DA - 2011// TI - Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma JO - Oral Oncol VL - 47 UR - https://doi.org/10.1016/j.oraloncology.2011.08.007 DO - 10.1016/j.oraloncology.2011.08.007 ID - Cho2011 ER - TY - JOUR AU - Mattox, A. K. AU - Lee, J. AU - Westra, W. H. AU - Pierce, R. H. AU - Ghossein, R. AU - Faquin, W. C. PY - 2017 DA - 2017// TI - PD-1 expression in head and neck squamous cell carcinomas derives primarily from functionally Anergic CD4(+) TILs in the presence of PD-L1(+) TAMs JO - Cancer Res VL - 77 UR - https://doi.org/10.1158/0008-5472.CAN-16-3453 DO - 10.1158/0008-5472.CAN-16-3453 ID - Mattox2017 ER - TY - JOUR AU - Ogunniyi, A. AU - Barbee, M. S. AU - Drilon, A. PY - 2016 DA - 2016// TI - Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer JO - Expert Rev Anticancer Ther VL - 16 UR - https://doi.org/10.1586/14737140.2016.1123626 DO - 10.1586/14737140.2016.1123626 ID - Ogunniyi2016 ER - TY - STD TI - Doroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, Chen L, et al. Immunotherapy in non-small cell lung Cancer: facts and hopes. Clin Cancer Res. 2019. ID - ref13 ER - TY - JOUR AU - Koemans, W. J. AU - Chalabi, M. AU - Sandick, J. W. AU - Dieren, J. M. AU - Kodach, L. L. PY - 2019 DA - 2019// TI - Beyond the PD-L1 horizon: in search for a good biomarker to predict success of immunotherapy in gastric and esophageal adenocarcinoma JO - Cancer Lett VL - 442 UR - https://doi.org/10.1016/j.canlet.2018.11.001 DO - 10.1016/j.canlet.2018.11.001 ID - Koemans2019 ER - TY - JOUR AU - Taube, J. M. AU - Klein, A. AU - Brahmer, J. R. AU - Xu, H. AU - Pan, X. AU - Kim, J. H. PY - 2014 DA - 2014// TI - Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy JO - Clin Cancer Res VL - 20 UR - https://doi.org/10.1158/1078-0432.CCR-13-3271 DO - 10.1158/1078-0432.CCR-13-3271 ID - Taube2014 ER - TY - JOUR AU - Li, Y. F. AU - Ding, J. W. AU - Liao, L. M. AU - Zhang, Z. L. AU - Liao, S. S. AU - Wu, Y. PY - 2017 DA - 2017// TI - Expression of programmed death ligand-1 predicts poor outcome in nasopharyngeal carcinoma JO - Mol Clin Oncol VL - 7 UR - https://doi.org/10.3892/mco.2017.1318 DO - 10.3892/mco.2017.1318 ID - Li2017 ER - TY - JOUR AU - Liu, Y. u. -. J. e. n. AU - Tsang, N. g. a. n. -. M. i. n. g. AU - Hsueh, C. h. u. e. n. AU - Yeh, C. h. i. -. J. u. AU - Ueng, S. h. i. r. -. H. w. a. AU - Wang, T. o. n. g. -. H. o. n. g. AU - Chuang, W. e. n. -. Y. u. PY - 2018 DA - 2018// TI - Low PD-L1 Expression Strongly Correlates with Local Recurrence in Epstein-Barr Virus-Positive Nasopharyngeal Carcinoma after Radiation-Based Therapy JO - Cancers VL - 10 UR - https://doi.org/10.3390/cancers10100374 DO - 10.3390/cancers10100374 ID - Liu2018 ER - TY - JOUR AU - Yang, W. F. AU - Wong, M. C. M. AU - Thomson, P. J. AU - Li, K. Y. AU - Su, Y. X. PY - 2018 DA - 2018// TI - The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: a systematic review and meta-analysis JO - Oral Oncol VL - 86 UR - https://doi.org/10.1016/j.oraloncology.2018.09.016 DO - 10.1016/j.oraloncology.2018.09.016 ID - Yang2018 ER - TY - JOUR AU - Zhou, Y. AU - Shi, D. AU - Miao, J. AU - Wu, H. AU - Chen, J. AU - Zhou, X. PY - 2017 DA - 2017// TI - PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load JO - Sci Rep VL - 7 UR - https://doi.org/10.1038/srep43627 DO - 10.1038/srep43627 ID - Zhou2017 ER - TY - JOUR AU - Fernandez-Medarde, A. AU - Santos, E. PY - 2011 DA - 2011// TI - Ras in cancer and developmental diseases JO - Genes Cancer VL - 2 UR - https://doi.org/10.1177/1947601911411084 DO - 10.1177/1947601911411084 ID - Fernandez-Medarde2011 ER - TY - JOUR AU - Zhang, J. W. AU - Qin, T. AU - Hong, S. D. AU - Zhang, J. AU - Fang, W. F. AU - Zhao, Y. Y. PY - 2015 DA - 2015// TI - Multiple oncogenic mutations related to targeted therapy in nasopharyngeal carcinoma JO - Chin J Cancer VL - 34 ID - Zhang2015 ER - TY - JOUR AU - Fang, W. AU - Zhang, J. AU - Hong, S. AU - Zhan, J. AU - Chen, N. AU - Qin, T. PY - 2014 DA - 2014// TI - EBV-driven LMP1 and IFN-gamma up-regulate PD-L1 in nasopharyngeal carcinoma: implications for oncotargeted therapy JO - Oncotarget. VL - 5 UR - https://doi.org/10.18632/oncotarget.2608 DO - 10.18632/oncotarget.2608 ID - Fang2014 ER - TY - JOUR AU - Yoshizaki, T. AU - Kondo, S. AU - Endo, K. AU - Nakanishi, Y. AU - Aga, M. AU - Kobayashi, E. PY - 2018 DA - 2018// TI - Modulation of the tumor microenvironment by Epstein-Barr virus latent membrane protein 1 in nasopharyngeal carcinoma JO - Cancer Sci VL - 109 UR - https://doi.org/10.1111/cas.13473 DO - 10.1111/cas.13473 ID - Yoshizaki2018 ER - TY - JOUR AU - Bi, X. W. AU - Wang, H. AU - Zhang, W. W. AU - Wang, J. H. AU - Liu, W. J. AU - Xia, Z. J. PY - 2016 DA - 2016// TI - PD-L1 is upregulated by EBV-driven LMP1 through NF-kappaB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma JO - J Hematol Oncol VL - 9 UR - https://doi.org/10.1186/s13045-016-0341-7 DO - 10.1186/s13045-016-0341-7 ID - Bi2016 ER - TY - JOUR AU - Hsu, M. C. AU - Hsiao, J. R. AU - Chang, K. C. AU - Wu, Y. H. AU - Su, I. J. AU - Jin, Y. T. PY - 2010 DA - 2010// TI - Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma JO - Mod Pathol VL - 23 UR - https://doi.org/10.1038/modpathol.2010.130 DO - 10.1038/modpathol.2010.130 ID - Hsu2010 ER - TY - JOUR AU - Chen, B. J. AU - Chapuy, B. AU - Ouyang, J. AU - Sun, H. H. AU - Roemer, M. G. AU - Xu, M. L. PY - 2013 DA - 2013// TI - PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies JO - Clin Cancer Res VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-13-0855 DO - 10.1158/1078-0432.CCR-13-0855 ID - Chen2013 ER - TY - JOUR AU - Zhao, L. AU - Liao, X. AU - Hong, G. AU - Zhuang, Y. AU - Fu, K. AU - Chen, P. PY - 2019 DA - 2019// TI - Mismatch repair status and high expression of PD-L1 in nasopharyngeal carcinoma JO - Cancer Manag Res VL - 11 UR - https://doi.org/10.2147/CMAR.S193878 DO - 10.2147/CMAR.S193878 ID - Zhao2019 ER - TY - JOUR AU - Zhang, J. AU - Fang, W. AU - Qin, T. AU - Yang, Y. AU - Hong, S. AU - Liang, W. PY - 2015 DA - 2015// TI - Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma JO - Med Oncol VL - 32 UR - https://doi.org/10.1007/s12032-015-0501-6 DO - 10.1007/s12032-015-0501-6 ID - Zhang2015 ER - TY - JOUR AU - Qu, Y. AU - Wang, D. AU - Yang, L. AU - Liu, H. Y. AU - Cui, W. AU - Che, Y. Q. PY - 2018 DA - 2018// TI - Expression and clinical significance of programmed death ligand 1 in nasopharyngeal carcinoma JO - Mol Clin Oncol. VL - 9 ID - Qu2018 ER - TY - JOUR AU - Lee, V. H. AU - Lo, A. W. AU - Leung, C. Y. AU - Shek, W. H. AU - Kwong, D. L. AU - Lam, K. O. PY - 2016 DA - 2016// TI - Correlation of PD-L1 expression of tumor cells with survival outcomes after radical intensity-modulated radiation therapy for non-metastatic nasopharyngeal carcinoma JO - PLoS One VL - 11 UR - https://doi.org/10.1371/journal.pone.0157969 DO - 10.1371/journal.pone.0157969 ID - Lee2016 ER - TY - JOUR AU - Chang, A. M. V. AU - Chiosea, S. I. AU - Altman, A. AU - Pagdanganan, H. A. AU - Ma, C. PY - 2017 DA - 2017// TI - Programmed death-ligand 1 expression, microsatellite instability, Epstein-Barr virus, and human papillomavirus in nasopharyngeal carcinomas of patients from the Philippines JO - Head Neck Pathol VL - 11 UR - https://doi.org/10.1007/s12105-016-0765-y DO - 10.1007/s12105-016-0765-y ID - Chang2017 ER - TY - JOUR AU - Larbcharoensub, N. AU - Mahaprom, K. AU - Jiarpinitnun, C. AU - Trachu, N. AU - Tubthong, N. AU - Pattaranutaporn, P. PY - 2018 DA - 2018// TI - Characterization of PD-L1 and PD-1 expression and CD8+ tumor-infiltrating lymphocyte in Epstein-Barr virus-associated nasopharyngeal carcinoma JO - Am J Clin Oncol VL - 41 UR - https://doi.org/10.1097/COC.0000000000000449 DO - 10.1097/COC.0000000000000449 ID - Larbcharoensub2018 ER - TY - JOUR AU - Lantuejoul, S. AU - Damotte, D. AU - Hofman, V. AU - Adam, J. PY - 2019 DA - 2019// TI - Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma JO - J Thorac Dis VL - 11 UR - https://doi.org/10.21037/jtd.2018.12.103 DO - 10.21037/jtd.2018.12.103 ID - Lantuejoul2019 ER - TY - JOUR AU - Marchetti, A. AU - Barberis, M. AU - Franco, R. AU - Luca, G. AU - Pace, M. V. AU - Staibano, S. PY - 2017 DA - 2017// TI - Multicenter comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) assays to test PD-L1 expression for NSCLC patients to be treated with immune checkpoint inhibitors JO - J Thorac Oncol VL - 12 UR - https://doi.org/10.1016/j.jtho.2017.07.031 DO - 10.1016/j.jtho.2017.07.031 ID - Marchetti2017 ER - TY - JOUR AU - Kerr, K. M. AU - Tsao, M. S. AU - Nicholson, A. G. AU - Yatabe, Y. AU - Wistuba, I. I. AU - Hirsch, F. R. PY - 2015 DA - 2015// TI - Programmed death-ligand 1 immunohistochemistry in lung Cancer: in what state is this art? JO - J Thorac Oncol VL - 10 UR - https://doi.org/10.1097/JTO.0000000000000526 DO - 10.1097/JTO.0000000000000526 ID - Kerr2015 ER - TY - JOUR AU - Chou, C. C. AU - Chou, M. J. AU - Tzen, C. Y. PY - 2009 DA - 2009// TI - PIK3CA mutation occurs in nasopharyngeal carcinoma but does not significantly influence the disease-specific survival JO - Med Oncol VL - 26 UR - https://doi.org/10.1007/s12032-008-9124-5 DO - 10.1007/s12032-008-9124-5 ID - Chou2009 ER - TY - JOUR AU - Houben, R. AU - Becker, J. C. AU - Kappel, A. AU - Terheyden, P. AU - Brocker, E. B. AU - Goetz, R. PY - 2004 DA - 2004// TI - Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis JO - J Carcinog VL - 3 UR - https://doi.org/10.1186/1477-3163-3-6 DO - 10.1186/1477-3163-3-6 ID - Houben2004 ER - TY - JOUR AU - Ma, B. B. Y. AU - Lim, W. T. AU - Goh, B. C. AU - Hui, E. P. AU - Lo, K. W. AU - Pettinger, A. PY - 2018 DA - 2018// TI - Antitumor activity of Nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the Mayo Clinic phase 2 consortium (NCI-9742) JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2017.77.0388 DO - 10.1200/JCO.2017.77.0388 ID - Ma2018 ER - TY - JOUR AU - Hsu, C. AU - Lee, S. H. AU - Ejadi, S. AU - Even, C. AU - Cohen, R. B. AU - Tourneau, C. PY - 2017 DA - 2017// TI - Safety and antitumor activity of Pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2017.73.3675 DO - 10.1200/JCO.2017.73.3675 ID - Hsu2017 ER - TY - JOUR AU - Anastasiadou, E. AU - Stroopinsky, D. AU - Alimperti, S. AU - Jiao, A. L. AU - Pyzer, A. R. AU - Cippitelli, C. PY - 2019 DA - 2019// TI - Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas JO - Leukemia. VL - 33 UR - https://doi.org/10.1038/s41375-018-0178-x DO - 10.1038/s41375-018-0178-x ID - Anastasiadou2019 ER -